Affimed

Affimed NV engages in the discovery and development of cancer immunotherapies. It is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company’s proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK platform predictably generates customized innate cell engager molecules, which use patient's immune cells to destroy tumor cells. The company was founded in 2000 and is headquartered in Heidelberg, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Affimed reports Q1 loss, positive clinical data in cancer treatments

Affimed's Q1 2024 performance showed a net loss but highlighted positive clinical data and progress in cancer treatments.
Despite enrollment delays in the LuminICE trial, Affimed's programs leveraging the innate immune system demonstrate consistency and success.
Addressing financial challenges, patient enrollment issues, and leveraging opportunities in future study phases and partnerships are key for Affimed's growth.

Affimed reports Q3 performance, highlights clinical milestones, and eyes partnerships

Affimed's Q3 2024 performance reflects a net loss of EUR 15.1 million but maintains a solid cash position of EUR 24.1 million.
Management's focus on clinical milestones, safety profiles, and upcoming updates at ASH 2024 demonstrates a commitment to innovation.
Challenges lie in meeting data expectations, navigating partnerships, and balancing financial stability with growth aspirations.
Opportunities abound in showcasing progress at ASH 2024, exploring partnerships, and advancing clinical programs for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Affimed NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of cancer immunotherapies. The company’s proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. It operates through the Germany and USA geographical segments. The company was founded in 2000 and is headquartered in Mannheim, Germany.

HEIDELBERG, Germany, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financial results for the third quarter ended September 30, 2022 and provided an update on clinical and corporate progress.

Affimed Reports Third Quarter 2022 Financial Results and Highlights Recent Clinical and Corporate Progress

Faraday Future Intelligent Electric

Sonnet BioTherapeutics

Tellurian

Tupperware

Penny stocks to watch this week. The post Best Penny Stocks To Buy?

Best Penny Stocks To Buy? 5 To Watch For November 2022

HEIDELBERG, Germany, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced data updates from two phase 1/2a trials with AFM24, the company's tetravalent, bispecific innate cell engager (ICE®), in patients with solid tumors. AFM24 binds both EGFR on tumor cells and CD16A on natural killer (NK) cells and macrophages, thereby facilitating the killing of EGFR-positive tumor cells. Abstracts for the upcoming data presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) were published today. The full updated clinical data sets will be presented in two poster presentations on November 10 and November 11, 2022 and will be made available through the following link on Affimed's website: Publications and Posters - Affimed

Affimed Provides Data Update from Two Phase 1/2a Trials with its Innate Cell Engager AFM24 in Solid Tumor Patients at the 37th SITC Annual Meeting

HEIDELBERG, Germany, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release third quarter 2022 results and corporate update on Tuesday, November 15, 2022. The Company will host a conference call at 8:30 a.m. EST / 14:30 CET.

Affimed to Report Third Quarter 2022 Financial Results & Corporate Update on November 15, 2022

HEIDELBERG, Germany and SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”), and Artiva Biotherapeutics Inc. (“Artiva”), both immuno-oncology companies focused on developing and commercializing therapies utilizing the innate immune system, today announced a new strategic partnership to jointly develop, manufacture, and commercialize a combination therapy comprised of Affimed's Innate Cell Engager (ICE®) AFM13 and Artiva's cord blood-derived, cryopreserved off-the-shelf allogeneic NK cell product candidate, AB-101.

Affimed and Artiva Biotherapeutics Announce Partnership to Advance Combination Therapy of Innate Cell Engager (ICE®) AFM13 and Off-the-Shelf Allogeneic NK Cell Therapy AB-101

HEIDELBERG, Germany, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced two upcoming data presentations at the American Society of Hematology (ASH) 2022 Annual Meeting.

Affimed Announces Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells and Preclinical AFM28 Data at ASH 2022 Annual Meeting

Affimed N.V. (AFMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Analysts Estimate Affimed N.V. (AFMD) to Report a Decline in Earnings: What to Look Out for

HEIDELBERG, Germany, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its Chief Executive Officer, Dr. Adi Hoess, will present at the 2022 Jefferies London Healthcare Conference on Wednesday, November 16, 2022, at 12:55 p.m. GMT / 7:55 a.m. EST / 13:55 CET.

Affimed to Present at the 2022 Jefferies London Healthcare Conference

Two poster presentations showing AFM24 as a monotherapy and combination treatment will be presented at the 37th Annual Meeting of the Society for Immunotherapy of Cancer, November 8-12, 2022. Results from the phase 2 registration REDIRECT study using AFM13 as a monotherapy for the treatment of patients with CD30-positive Peripheral T-cell lymphoma expected Q4 of 2022.

Affimed: Data Readout Of AFM13 This Quarter Could Push Company Forward

An analyst's downgrade brings out the bears for the European cancer treatment developer.

Why Affimed Stock Plummeted by Over 16% Today

HEIDELBERG, Germany, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that two abstracts with new data on the company's novel innate cell engager (ICE®) AFM24 have been accepted for poster presentation at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). The conference will take place on November 8-12, 2022, in Boston, MA.

Affimed Announces Two Clinical Update Presentations on its Novel Bispecific Innate Cell Engager AFM24 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

HEIDELBERG, Germany, Sept. 04, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that an abstract with clinical trial results of its innate cell engager (ICE®) AFM24 has been accepted for a poster presentation at the Congress of the European Society for Medical Oncology (ESMO) from 9-13 September 2022 in Paris.

Affimed To Provide a Clinical Update on AFM24 Monotherapy Dose-escalation at European Society for Medical Oncology (ESMO) Congress 2022

HEIDELBERG, Germany, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that the Company's management will participate in the following investor conferences during the month of September 2022.

Affimed to Present at Upcoming Investor Conferences

Cerus

Replimune Group Inc

This billionaire-guided hedge fund went bargain-shopping in the second quarter.

Billionaires Are Scooping Up These 3 Beaten-Down Biotech Stocks

Affimed NV (NASDAQ:AFMD ) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Alexander Fudukidis - Head, IR Adi Hoess - CEO Angus Smith - CFO Andreas Harstrick - Chief Medical Officer Conference Call Participants Daina Graybosch - SVB Securities Maurice Raycroft - Jefferies Li Watsek - Cantor Fitzgerald & Co. Zhiqiang Shu - Berenberg Yale Jen - Laidlaw & Company Bijan Mekoba - Stifel, Nicolaus & Company Operator Good day, everyone, and welcome to the Affimed Second Quarter 2022 Financial Results and Corporate Update Conference Call. My name is Vanessa, and I will be your operator for today's call.

Affimed NV (AFMD) CEO Adi Hoess on Q2 2022 Results - Earnings Call Transcript

Affimed N.V. (AFMD) delivered earnings and revenue surprises of 22.22% and 4.22%, respectively, for the quarter ended June 2022.

Affimed N.V. (AFMD) Reports Q2 Loss, Lags Revenue Estimates

HEIDELBERG, Germany, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financial results for the second quarter ended June 30, 2022 and provided updates on preclinical, clinical and corporate progress.

Affimed Reports Second Quarter 2022 Financial Results and Highlights Recent Operational Progress

HEIDELBERG, Germany, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release second quarter 2022 results and corporate update on Thursday, August 11, 2022. The Company will host a conference call at 8:30 a.m. Eastern Daylight Time.

Affimed to Report Second Quarter 2022 Financial Results & Corporate Update on August 11, 2022

Aurora Cannabis

PlayAGS

CuriosityStream

Edgewise Therapeutics

Gevo

This article is about 6 blue-chip stocks to sell now. The stocks are overvalued or could fall due to the recession or from a downgrade in analysts' forecasts of their earnings.

6 Blue-Chip Stocks to Sell Now

HEIDELBERG, Germany, June 30, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today the establishment of a Scientific Advisory Board (SAB) of renowned experts in their respective fields to provide scientific and clinical guidance on the development of Affimed's innate cell engagers (ICE®) programs.

Affimed Establishes Scientific Advisory Board

Affimed has generated an impressive pipeline of innate cell engagers programs created using their three-pronged development strategy. These programs target high unmet needs and large market opportunities. Affimed recently finalized a $103.5M public offering, which will help fund the company's wholly-owned programs to hit key catalysts over the remainder of 2022 and into 2023.

Affimed: Preparing For Key Inflection Points

HEIDELBERG, Germany, June 10, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today presented a poster at the Annual Meeting of the European Hematology Association (EHA) in Vienna, Austria. The data demonstrate the cytotoxic potential of the CD123/CD16A-targeting bispecific innate cell engager (ICE®) AFM28 which is in development as a novel treatment for patients with myeloid diseases, e. g. relapsed/refractory (R/R) acute myeloid leukemia (AML). AFM28 binds to natural killer (NK) cells and CD123-positive tumor cells and demonstrated the induction of tumor cell killing in vitro and a good tolerability and strong anti-tumor activity in vivo.

Affimed Presents Preclinical Data of Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA)

Affimed N.V. (NASDAQ:AFMD ) Q1 2022 Results Conference Call June 1, 2022 8:30 AM ET Company Participants Alex Fudukidis - Head of Investor Relations Adi Hoess - Chief Executive Officer Andreas Harstrick - Chief Medical Officer Arndt Schottelius - Chief Scientific Officer Wolfgang Fischer - Chief Operating Officer Angus Smith - Chief Financial Officer Conference Call Participants Daina Graybosch - SVB Securities Kripa Devarakonda - Truist Securities Maury Raycroft - Jefferies Li Watsek - Cantor Brad Canino - Stifel Do Kim with - Sandler Yale Jen - Laidlaw Nick Abbott - Wells Fargo Operator Good day and thank you for standing by.

Affimed N.V. (AFMD) CEO Adi Hoess on Q1 2022 Results - Earnings Call Transcript

Affimed N.V. (AFMD) delivered earnings and revenue surprises of 11.11% and 9.57%, respectively, for the quarter ended March 2022.

Affimed N.V. (AFMD) Reports Q1 Loss, Misses Revenue Estimates

HEIDELBERG, Germany, June 01, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financial results for the first quarter ended March 31, 2022 and provided an update on clinical and corporate progress.

News for Affimed Stock (AFMD)